Dublin, May 05, 2023 (GLOBE NEWSWIRE) -- The "Global Active Pharmaceutical Ingredients Market 2022-2032 by Molecule, Synthesis, Manufacturing Process, Therapeutic Application, Drug Type, and Region: Trend Forecast and Growth Opportunity" report has been added to ResearchAndMarkets.com's offering.
Global active pharmaceutical ingredients (API) market will reach $ 386.2 billion by 2032, growing by 6.4% annually over 2022-2032, driven by rising adoption of biologics in disease management, increasing regulatory approvals, patent expiration of major drugs, growing trend of outsourcing and increase in geriatric population.
This 258-page report is based on a comprehensive research of the entire global active pharmaceutical ingredients (API) market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2020-2022 and provides forecast from 2023 till 2032 with 2022 as the base year.
In-depth qualitative analyses include identification and investigation of the following aspects:
- Market Structure
- Growth Drivers
- Restraints and Challenges
- Emerging Product Trends & Market Opportunities
- Porter's Five Forces
The trend and outlook of global market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19 and Russia-Ukraine conflict. The balanced (most likely) projection is used to quantify global active pharmaceutical ingredients (API) market in every aspect of the classification from perspectives of Molecule, Synthesis, Manufacturing Process, Therapeutic Application, Drug Type, and Region.
Based on Molecule, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
- Small Molecule APIs
- Large Molecule APIs
Based on Synthesis, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
- Synthetic API
- Branded Synthetic API
- Generic Synthetic API
- Biotech API
- by type
- Monoclonal Antibodies
- Recombinant Proteins
- Vaccines
- Other Biotech APIs
- by Category
- Innovative Biologic API
- Generic Biosimilar API
- by Expression
- Mammalian Expression
- Microbial Expression
- Yeast Expression
- Insect Expression
- Other Expression Technologies
- HPAPI
- Branded HPAPI
- Generic HPAPI
Based on Manufacturing Process, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
- Captive Manufacturing
- Branded Captive API
- Generic Captive API
- Merchant Manufacturing
- by Drug Type
- Branded Merchant API
- Generic Merchant API
- by Drug Synthesis
- Merchant Synthetic API
- Merchant Biotech API
By Therapeutic Application, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
- Infectious Diseases
- Oncology
- Ophthalmology
- Cardiovascular Disorders
- Central Nervous System
- Pulmonary Disorders
- Orthopedics
- Other Applications
By Drug Type, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
- Branded Prescription Drugs
- Generic Prescription Drugs
- OTC Drugs
Geographically, the following regions together with the listed national/local markets are fully investigated:
- North America (U.S., Canada, and Mexico)
- Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe; Rest of Europe is further segmented into Netherlands, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland)
- APAC (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)
- South America (Brazil, Chile, Argentina, Rest of South America)
- MEA (UAE, Saudi Arabia, South Africa and Rest of MEA)
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 258 |
| Forecast Period | 2022 - 2032 |
| Estimated Market Value (USD) in 2022 | $207600 Million |
| Forecasted Market Value (USD) by 2032 | $386200 Million |
| Compound Annual Growth Rate | 6.4% |
| Regions Covered | Global |
Key Topics Covered:
1 Introduction
2 Market Overview and Dynamics
3 Segmentation of Global Market by Molecule
4 Segmentation of Global Market by Synthesis
5 Segmentation of Global Market by Manufacturing Process
6 Segmentation of Global Market by Therapeutic Application
7 Segmentation of Global Market by Drug Type
8 Segmentation of Global Market by Region
9 Competitive Landscape
Companies Mentioned
- AbbVie Inc.
- Astrazeneca
- Aurobindo Pharma Ltd.
- BASF
- Bayer AG
- Boehringer Ingelheim
- Catalent Inc.
- Dr. Reddy's Laboratories
- F. Hoffmann-La Roche
- GlaxoSmithKline plc
- Lonza Group
- Lupin Limited
- Merck & Co., Inc.
- Mylan NV
- Novartis International AG
- Pfizer Inc.
- Sanofi
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Industries Ltd.
- Thermo Fisher Scientific
For more information about this report visit https://www.researchandmarkets.com/r/7rijah
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
